Saturday 17 October 2026
Export CLYM’s income statement to Excel — free account
Climb Bio, Inc.
CLYM Healthcare Biotechnology
In the quarter to June 2026, EPS fell 38.5% and free cash flow grew 3.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.82
1.09
−9.99%
Follow CLYM
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 8.16 | 2.36 | 2.21 | 1.73 | 1.05 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 29.69 | 13.74 | 4.75 | 11.55 | 5.05 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 25 | 31 | 43 | 11 | 18 | 28 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | (7) | (21) | (47) | (45) | (35) | (74) | (60) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (7) | (21) | (47) | (45) | (35) | (74) | (60) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | (2) | (1) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.28) | (9.45) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) | |||||
| Cash flow | — | — | — | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) | |||||
| Book value | — | — | — | 0.78 | (11.42) | 13.64 | 4.89 | 3.99 | 4.40 | 2.37 | |||||
| Shares, m | — | — | — | 26 | 2 | 12 | 26 | 27 | 48 | 68 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (14) | (36) | (37) | (21) | (16) | (54) | ||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | |||||
| Free cash flow | — | — | — | (5) | (14) | (36) | (37) | (21) | (16) | (55) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 21 | 19 | 142 | 128 | 107 | 150 | 99 | ||||
| Total debt | — | — | — | — | — | — | 0 | — | — | — | |||||
| Net debt | — | — | — | (21) | (20) | (136) | (124) | (107) | (151) | (101) | |||||
| Shareholders’ equity | — | — | — | 21 | (25) | 167 | 129 | 108 | 212 | 160 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (69.09) | (99.74) | (52.59) | (29.36) | (28.61) | (45.11) | (31.10) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (72.57) | (547.86) | (3,142.56) | (84.09) | (71.43) | |||||
| ROE | — | — | — | 48.39 | 150.29 | (73.17) | (30.58) | (29.72) | (46.26) | (32.15) | |||||
Negative figures in brackets.
Charts ten years each
Climb Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| AVTX Avalo Therapeutics, Inc. | $644.1M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $628.6M | — (loss-making) | — (loss-making) | −73.88% (below 0%: shrinking) | n/m | −17.59% (below 0%: shrinking) | 100.00% | (3,248.33%) | Compare |
| CLYM Climb Bio, Inc. | $626.6M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | |
| NVCT Nuvectis Pharma, Inc. | $618.0M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | Compare |
| SLDB Solid Biosciences Inc. | $615.5M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ZVRA Zevra Therapeutics, Inc. | $609.9M | 10.5× | 10.5× | +53.25% (above 0%: growing) | −88.71% (below 0%: shrinking) | +670.87% (above 0%: growing) | 96.16% | 42.30% | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $606.8M | — (loss-making) | — (loss-making) | +88.02% (above 0%: growing) | n/m | +96.86% (above 0%: growing) | 79.68% | (5.34%) | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $601.1M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $616.7M | — | — | −33.32% | — | −6.60% | 79.68% | 0.00% |
Climb Bio, Inc. (CLYM) key facts
- Climb Bio, Inc. (CLYM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CLYM traded at $9.82, a market capitalization of $626.6 million.
- Return on equity was −32.2% and debt-to-equity 0.00.
Climb Bio, Inc. (CLYM) Latest News
No news at this impact. Lower the threshold for more.